Picamilon, a γ-aminobutyric acid (GABA) analogue and marketed nootropic, is inactive against 50 biological targets
Lab research · 2023
- What was studied
- 50 biological targets; computational and in-vitro screening
- Main finding
- Picamilon showed weak or no binding at 10 μM across the tested panel. This does not exclude other targets, metabolites or effects at other concentrations.
Study data at a glance
- Participants or experimental model
- 50 biological targets; computational and in-vitro screening
- Reported results
- Picamilon showed weak or no binding at 10 μM across the tested panel. This does not exclude other targets, metabolites or effects at other concentrations.
Study limitations and source details
Study limitations
- Full methods and risk of bias have not been appraised.
- These findings do not establish long-term, combination or hazardous-work safety.
- Related reports may share participants; source records are not independent-trial counts.
Source details
Indexed citation and abstract checked through Europe PMC; full paper not reviewed.
Sources checked
Citation
Santillo MF, Sprando RL. Picamilon, a γ-aminobutyric acid (GABA) analogue and marketed nootropic, is inactive against 50 biological targets Basic & clinical pharmacology & toxicology 132(4). PMID 36668678
Study source ↗ · DOI 10.1111/bcpt.13836 · Bibliography entry · Link to this summary